KMT2A and acute lymphoblastic leukemia: In MLL-rearranged ALL, oncogenic KRAS has itself been shown to act as a cooperative lesion and the introduction of KRAS mutations into MLL/AF4 transgenic mice results in a more aggressive leukemic phenotype, which more closely mirrors the human equivalent (70, 71).